In Dexcom’s latest earnings report, executives reported not only growing revenues and sales volume for the company, but a sense that the whole category of CGMs has arrived and is transforming diabetes care for the better, noting trends observed at the recent annual meeting of the American Diabetes Association.
“We have been on record for years telling that the future is ‘CGM First’ and we believe...
Roughly a year after its launch, Walgreens Boots Alliance announced that its Find Care platform — a mobile and web tool guiding consumers toward curated health services — has added eight new partners including Propeller Health, Dexcom and a handful of regional health systems.
The two digital companies’ connected inhaler sensors and CGM devices add new chronic care management options to the retail...
For folks managing their diabetes with Dexcom, Siri can now answer one more question: What is my glucose level? This morning Dexcom announced a slew of new companion app features for the Dexcom G6 continuous glucose monitoring system, including the ability for Siri to read a user’s glucose level out loud and display graphs directly on the lock screen.
The app, which was released in 2018, will...
Dexcom held its Q4 2018 earnings call last week, reporting an overall very strong year, but also announcing outsourcing plans that will likely lead to layoffs in the US.
The company broke $1 billion in annual revenue in 2018, CEO Kevin Sayer said on the call, while increasing adoption, especially in Medicare and international markets, both of which are new to the company. And the company has set...
On its third quarter earnings call last week, Dexcom recapped a busy Q3 — of note, one that included the acquisition of TypeZero Technologies for $11.3 million in August as well as two new FDA clearances in October and November. One of these clearances was for a new mobile app interface for the Dexcom G6 while the other was the Dexcom Pro Q CGM, a new disposable glucose monitoring device intended...
Shortly after launching its integrated continuous glucose monitoring system, Dexcom announced a 42 percent increase in year-over-year sales during its Q2 earnings call.
“Not only did we exceed our annual growth guidance for the second consecutive quarter but the business continues to accelerate,” Kevin Ronald Sayers, CEO of Dexcom, said during the call. “All of our key segments demonstrated...
Dexcom started out the year strong following the FDA clearance of its integrated continuous glucose monitor the G6. In its Q1 earnings call, the company reported a 30 percent increase in revenue compared to Q1 of 2017, bringing its total revenue to $184 million.
When the FDA gave Dexcom the nod for the G6 it became the first interoperable CGM to get the designation. According to the earnings call...
Yesterday Dexcom got the nod from the FDA to market their Dexcom G6, an integrated continuous glucose monitoring system (iCGM), making it the first interoperable CGM to get the designation.
“We are a company of firsts, almost everything that has been done in our industry has been done by us first,” Dexcom CEO Kevin Sayer told MobiHealthNews, citing that Dexcom was the first company to have a...
Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some time assuaging investor fears about that friction.
“Late in the third quarter, the FDA approved Abbott's FreeStyle Libre flash glucose monitoring system,” Sayer said on the call. “We always believed the...
After the latest in a series of successful quarters (with $171.2 million in revenue, up 31 percent year over year), DexCom is queuing up some big product launches. On yesterday’s Q4 earnings call, CEO Kevin Sayer provided more detail about the forthcoming G6 continuous glucose monitor as well as the first products to come out of DexCom’s partnership with Verily.
“In a year of much confusion and...
